Siiri Altraja

https://www.etis.ee/CV/Siiri_Altraja/est
15.06.1965
737 4313
siiri.altraja@ut.ee

Teenistuskäik

Töökohad ja ametid
1988-91: nooremteadur, Immunoloogia Labor,
Tartu Ülikool, Eesti;
1991-93: Magistrantuur, Tartu Ülikool, Eesti;
1993-96: külalisuurija, Meditsiinilise
Mikrobioloogia Instituut, Lundi Ülikool, Rootsi;
1996-2000: Doktorantuur, Infektsioonhaiguste ja
Meditsiinilise Mikrobioloogia Instituut, Lundi
Ülikool, Rootsi.
Alates 2001: Eesti Biokeskus, vanemteadur,
alates 2002: Tartu Ülikooli Molekulaar- ja
Rakubioloogia Instituut, vanemteadur
Lisaks teadustöö: 1) Biokeemia Instituut, Kieli
Ülikool, Saksamaa 6 korral alates märts 1994
kokku 8 kuud; 2). Kaitsejõudude
Uurimisinstituut, Umeå, Rootsi ja Odontoloogia
kateeder, Umeå Ülikool, Rootsi alates nov. 1996,
kokku 5 kuud; 3). Meditsiinilise Biokeemia
Instituut, Göteborgi Ülikool, Rootsi (sügis
1999);
4) Proteoomika Keskus, Aberdeeni Ülikool,
Suurbritannia (sept. 2001)
01.02.2017–28.03.2018   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, üldise biokeemia lektor (0,75)
01.01.2016–31.12.2016   
Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut, mass-spektromeetria spetsialist (0,90)
01.04.2015–31.12.2015   
Tartu Ülikool, Arstiteaduskond, Biomeditsiini instituut, mass-spektromeetria spetsialist (0,90)
01.01.2015–31.03.2015   
Tartu Ülikool, Arstiteaduskond, Biomeditsiini instituut, mass-spektromeetria spetsialist (1,00)
21.05.2013–31.12.2014   
Tartu Ülikool, Arstiteaduskond, Biomeditsiini instituut, biotehnoloogia vanemteadur (0,50)
2013–2013   
Tartu Ülikool, Arstiteaduskond, Üld- ja molekulaarpatoloogia instituut, Inimese bioloogia ja geneetika õppetool, biotehnoloogia vanemteadur (1,00)
2012–2012   
Tartu Ülikool, Arstiteaduskond, Üld- ja molekulaarpatoloogia instituut, Inimese bioloogia ja geneetika õppetool, biotehnoloogia vanemteadur
01.03.2007–28.02.2012   
Tartu Ülikool, Arstiteaduskond, Üld- ja molekulaarpatoloogia instituut, biotehnoloogia vanemteadur (1,00)
01.11.2006–28.02.2007   
Tartu Ülikool, Arstiteaduskond, Üld- ja molekulaarpatoloogia instituut, biotehnoloogia erakorraline vanemteadur (1,00)
01.11.2001–31.10.2006   
Tartu Ülikool, Bioloogia-geograafiateaduskond, Molekulaar- ja rakubioloogia instituut, biotehnoloogia vanemteadur (1,00)
 
 
Haridustee
1996–2000   
Doktorantuur, Infektsioonhaiguste ja Meditsiinilise Mikrobioloogia Instituut, Lundi Ülikool, Rootsi
1991–1993   
Magistrantuur, Tartu Ülikool, Eesti;
1983–1988   
Füüsika-Keemiateaduskond; eriala: biokeemia, Tartu Ülikool, Eesti;
 
 
Teadusorganisatsiooniline ja -administratiivne tegevus
2003−...   
Ekspert EU grantide hindamiskomisjonis
2003−...   
Euroopa Kopsuarstide Assotsiatsiooni liige
1999−...   
1) Täienduskursuse "Microbial Adhesion and Virulence" (Kopenhaagen/ Lund) organiseerimiskomitee liige
2002−2006   
Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituudi teadussekretär 2002-2006

Kvalifikatsioon

Teaduskraadid
Siiri Altraja, doktorikraad, 2000, (juh) Torkel Wadström, Helicobacter pylori sialic acid-specific surface lectin, University of Lund, Sweden.
 
 
Teaduspreemiad ja tunnustused
2000, Siiri Altraja, Vabariigi Presidendi Kultuurirahastu "Noore teadlase preemia" konkursil äramärkimist väärinud teadustöö
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.1. Biomeditsiin; TÄPSUSTUS: 1. Helicobacter pylori cell surface proteins; 2. Ribosome-associated proteins of eucaryotic cells and the respective genes 3. Airway remodeling and disease markers in obstructive pulmonary diseases
 
 
Lisainfo
Ph.D (meditsiin)
Lundi Ülikool, Rootsi; 2000

Lõppenud projektid

Juhendamisel väitekirjad

Juhendatud väitekirjad

Publikatsioonid

Klass
Aasta
Publikatsioon
 
1.1.
2018
Kilk, Kalle; Aug, Argo; Ottas, Aigar; Soomets, Ursel; Altraja, Siiri; Altraja, Alan (2018). Phenotyping of Chronic Obstructive Pulmonary Disease Based on the Integration of Metabolomes and Clinical Characteristics. International Journal of Molecular Sciences, 19 (3), ARTN 666.10.3390/ijms19030666.
5.1.
2017
Altraja, S.; Mitt, M.; Altraja, A. (2017). Altered Expression of Genes Involved in Inflammatory Response and Fibrosis by Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Relation to the Effect of Cigarette Smoke. American Journal of Respiratory and Critical Care Medicine, 195, A3070−A3070.
5.1.
2016
Altraja, S.; Mitt, M.; Altraja, A. (2016). Altered gene expression profiles in human bronchial epithelial cells exposed to e-cigarette liquid: results from a genome-wide monitoring. American Journal of Respiratory and Critical Care Medicine, 193, A4053.
5.1.
2016
Altraja, S.; Mitt, M.; Altraja A. (2016). Leukotriene E4 affects expression of genes involved in inflammatory, remodelling and mitogenic responses in human bronchial epithelial cells. European Respiratory Journal, 48 (Suppl.60), PA948.
5.1.
2015
Altraja, S.; Altraja, A. (2015). Bay u9773 and ticagrelor inhibit the LTE4-induced overexpression of the P2Y12 receptor on human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 191, A1277.
5.2.
2015
Altraja, A.; Aug, A.; Kilk, K.; Mahlapuu, R.; Altraja, S.; Soomets, U. (2015). Phenotyping of COPD by integrated metabolomic profiling of exhaled breath condensate and peripheral blood. European Respiratory Journal, 46 (Suppl.59), OA2922.
5.2.
2015
Altraja, S.; Mitt, M.; Altraja, A. (2015). Gene expression changes in human bronchial epithelial cells in response to leukotriene E4. European Respiratory Journal, 46 (Suppl. 59), PA860.
5.2.
2015
Altraja, S.; Mitt, M.; Altraja, A. (2015). General gene expression analysis of human bronchial epithelial cells exposed to different concentrations of leukotriene E4. European Clinical Respiratory Journal, 2, 28179.
5.1.
2014
Aug, A.; Altraja, S.; Kilk, K.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2014). E-cigarettes profoundly affect metabolome of primary human bronchial epithelial cells. European Respiratory Journal, 44 (Suppl. 58), 1834.
1.1.
2013
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2013). Cigarette smoke-induced differential regulation of glutathione metabolism in bronchial epithelial cells is balanced by an antioxidant tetrapeptide UPF1. Experimental and Toxicologic Pathology, 65 (6), 711−717.10.1016/j.etp.2012.09.005.
5.1.
2013
Aug, A.; Altraja, S.; Kilk, K.; Laaniste, L.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2013). Acute effect of cigarette smoke on human bronchial epithelial cell metabolome is reversible by UPF1. European Respiratory Journal, 42, 819s.
5.1.
2013
Altraja, S.; Altraja, A. (2013). Down-regulation of the P2Y12 purinergic receptor expression on human bronchial epithelial cells by transforming growth factor-β. European Respiratory Journal, 42, 1009s−1010s.
5.1.
2013
Altraja, S.; Altraja, A. (2013). Up-regulation of the expression of the P2Y12 purinergic receptor on human bronchial epithelial cells by leukotriene E4. American Journal of Respiratory and Critical Care Medicine, 187, A4191.
5.2.
2013
Altraja, S.; Altraja, A. (2013). Analysis of P2Y12 purinergic receptor expression on human bronchial epithelial cells. Proceedings of the 46th Nordic Lung Congress; (Reykjavik, 13-15 June 2013). 59−60.
1.2.
2012
Altraja, A.; Nigol, K.; Altraja, S.; Viitak, A. (2012). Increased bronchoalveolar lavage fluid tin content in stannosis. Chest Disease Reports, 2 (1), 26−28.10.4081/cdr.2012.e8.
5.2.
2012
Aug, A.; Altraja, S.; Kilk, K.; Laaniste, L.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2012). Antioxidant tetrapeptide UPF1 exerts an immediate effect on cigarette smoke-altered metabolic state of human bronchial epithelial cells. European Respiratory Journal, 40, 837s.
5.2.
2012
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2012). The effect of an antioxidant tetrapeptide UPF1 on glutathione metabolism in human bronchial epithelial cells exposed to cigarette smoke. American Journal of Respiratory and Critical Care Medicine, 185, A1256.
1.1.
2010
Altraja, S.; Jaama, J.; Altraja, A. (2010). Proteome changes of human bronchial epithelial cells in response to pro-inflammatory mediator leukotriene E4 and pro-remodelling factor TGF-β1. Journal of Proteomics, 73 (6), 1230−1240.10.1016/j.jprot.2010.02.017.
5.1.
2010
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2010). An antioxidant tetrapeptide UPF1 maintains glutathione level in normal human bronchial epithelial cells exposed to oxidative stress. American Journal of Respiratory and Critical Care Medicine, 181, A2686.
1.1.
2009
Altraja, S.; Jaama, J.; Valk, E.; Altraja, A. (2009). Changes in the proteome of human bronchial epithelial cells following stimulation with leukotriene E4 and transforming growth factor-b1. Respirology, 14 (1), 39−45.10.1111/j.1440-1843.2008.01414.x.
3.2.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Changes in the proteome of human bronchial epithelial cells in response to leukotriene E4 and TGF-b1. Marko-Varga, G.; Laurell, T.. Proceedings of 3rd EUPA Congress: Clinical Proteomics (395−397).. Veszprem, Hungary: OOK-PRESS Kft..
5.1.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Cysteinyl leukotrienes cause down-regulation of glucocorticoid receptor in human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 179, A1403.
5.2.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Cysteinyl leukotrienes cause down-regulation of β-tubulin isotype IV in human bronchial epithelial cells. European Respiratory Journal, 34(Suppl.53), 51S.
1.1.
2008
Altraja, S.; Kadai., M; Rekker, E.; Altraja, A. (2008). Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. Respiratory Research, 9 (44), 1−12.10.1186/1465-9921-9-44.
5.2.
2008
Altraja, S.; Jaama, J.; Altraja, A. (2008). Proteome changes of human bronchial epithelial cells in response to leukotriene E4 and TGF-beta1. European Respiratory Journal 32 (Supple 52). 341s.
5.2.
2008
Altraja, S.; Rekker, E.; Altraja, A. (2008). Upregulation of cysteinyl leukotriene receptor expression on human bronchial epithelial cells by cysteinyl leukotrienes alone and with inflammatory cytokines. American Journal of Respiratory and Critical Care Medicine, 177, A16.
5.2.
2007
Altraja, S.; Rekker, E.; Altraja, A. (2007). Cysteinyl leukotriene-induced upregulation of tenascin and laminin beta2 chain in human bronchial epithelial cells is mediated by the CysLT1 receptor. European Respiratory Journal, 30. 217s.
5.2.
2007
Altraja, S.; Valk, E:; Rekker, E.; Altraja, A. (2007). Oxidative stress enhances expression of extracellular matrix proteins in bronchial epithelial cells. European Respiratory Journal, 30. 219s.
5.2.
2007
Altraja, S.; Rekker, E.; Altraja, A. (2007). Cysteinyl leukotriene-induced upregulation of tenascin in human bronchial epithelial cells is mediated by the CysLT1 receptor. American Journal of Respiratory and Critical Care Medicine, 175. A688.
1.1.
2006
Aspholm, M.; Olfat, F.O.; Nordén, J.; Sondén, B.; Lundberg, C.; Sjöström, R.; Altraja, S.; Odenbreit, S.; Haas, R.; Wadström, T.; Engstrand, L.; Semino-Mora, C.; Liu, H.; Dubois, A.; Teneberg, S.; Arnqvist, A.; Borén, T. (2006). SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathogens, 2 (10), 0989−1001.
5.2.
2006
Altraja, S; Rekker, E; Altraja, A. (2006). Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-b1 and LTE4 on human bronchial epithelial cells. European Respiratory Journal, 28. 564s. ((Suppl. 50)).
5.2.
2006
Altraja, S.; Valk, E.; Altraja, A. (2006). Changes in the proteome of human bronchial epithelial cells in response to proinflammatory mediators. Proceedings of the American Thoracic Society, 3. A309.
5.2.
2005
Altraja, S.; Kadai, M.; Altraja, A. (2005). Expression of the cysteinyl leukotriene receptors CysLT1 and CysLT2 in the airway structural cells. European Respiratory Journal, 26, 346s.
5.2.
2005
Altraja, S.; Rekker, E.; Altraja, A. (2005). Cysteinyl leukotrienes enhance expression of tenascin and laminin beta2 chain by human lung fibroblasts. Proceedings of the American Thoracic Society. A76. (2).
5.2.
2004
Altraja, A.; Kadai, M.; Altraja, S. (2004). Cysteinyl leukotrienes increase tenascin expression by human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 169. A454. (Supplement).
5.2.
2004
Altraja, S.; Kadai, M.; Altraja, A. (2004). Oxidative stress in bronchial epithelial cells: relations to extracellular matrix synthesis. European Respiratory Journal, 48. 106s. (24).
5.2.
2003
Altraja, S.; Kadai, M.; Altraja, A. (2003). Leukotriene E4 increases tenascin production by human bronchial epithelial cells. European Respiratory Journal. 36s. (22).
1.1.
2002
Mahdavi, J.; Forsberg, L.; Teneberg, S.; Karlsson, KA.; Altraja, S.; et, al. (2002). Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science, 297 (5581), 573−578.
1.1.
2001
Wang, X.; Hirmo, S.; Willen, R.; Wadstrom, T. (2001). Inhibition of Helicobacter pylori infection by bovine milk glycoconjugates in a BALB/cA mouse model. Journal of Medical Microbiology, 50 (5), 430−435.
1.1.
2001
Annuk, H.; Hynes, SO.; Hirmo, S.; Mikelsaar, M.; Wadstrom, T. (2001). Characterisation and differentiation of lactobacilli by lectin typing. Journal of Medical Microbiology, 50 (12), 1069−1074.
3.2.
2001
Arnqvist, A.; Ilver, D.; Ögren, J.; Hirmo, S.; Wadström, T.; Boren, T. (2001). Adherence of Helicobacter pylori: Mechanisms and Relevance to Pathogenesis. In: Moran, A.P. (_EditorsAbbr). Helicobacter 2001:Past, Present and Future (CD-ROM).. Englewood, NJ, USA: Normed Verlag Inc, Englewood.
3.2.
2001
Gerhard, M.; Hirmo, S.; Wadström, T.; Miller-Podraza, H.; Teneberg, S.; Karelsson, K.; Appelmelk, B.; Odenbreit, S.; Haas, R.; Arnqvist, A.; Boren, T. (2001). Helicobacter pylori, An Adherent Pain in the Stomach. In: Helicobacter pylori: Molecular and Cellular Biology (185−206).. Norfolk, U.K. : Horizon Scientific Press.
5.1.
2000
Wang, X.; Hirmo, S.; Willen, R.; Wadstrom, T. (2000). Inhibition of H-pylori infection by bovine milk glycoconjugates in a mouse model. GUT, 47, A60−A60.
1.1.
1999
Annuk, H.; Hirmo, S.; Turi, E.; Mikelsaar, M.; Arak, E.; Wadstrom, T. (1999). Effect on cell surface hydrophobicity and susceptibility of Helicobacter pylori to medicinal plant extracts. FEMS Microbiology Letters, 172 (1), 41−45.
1.1.
1999
Hirmo, S.; Artursson, E.; Puu, G.; Wadstrom, T.; Nilsson, B. (1999). Helicobacter pylori interactions with human gastric mucin studied with a resonant mirror biosensor. Journal of Microbiological Methods, 37 (2), 177−182.
1.1.
1999
Hynes, SO.; Hirmo, S.; Wadstrom, T.; Moran, AP. (1999). Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. Journal of Clinical Microbiology, 37 (6), 1994−1998.
1.1.
1998
Hirmo, S.; Artursson, E.; Puu, G.; Wadstrom, T.; Nilsson, B. (1998). Characterization of Helicobacter pylori interactions with sialylglycoconjugates using a resonant mirror biosensor. Analytical Biochemistry, 257 (1), 63−66.
1.1.
1998
Hirmo, S.; Kelm, S.; Iwersen, M.; Hotta, K.; Goso, Y.; Ishihara, K.; Suguri, T.; Morita, M.; Wadstrom, T.; Schauer, R. (1998). Inhibition of Helicobacter pylori sialic acid-specific haemagglutination by human gastrointestinal mucins and milk glycoproteins. FEMS Immunology and Medical Microbiology, 20 (4), 275−281.
3.1.
1998
Chmiela, M.; Paziak-Domanska, B.; Hirmo, S.; Rudnicka, W.; Utt, M.; Wadström, T. (1998). Helicobacter pylori - interactions with phagocytes. In: Hunt R.H., Tytgat G.N.J. (Ed.). Helicobacter pylori : basic mechanisms to clinical cure 1998 (90−100).. Dordrecht, Boston, London: Kluwer Academic Publishers.
3.4.
1998
Hirmo, S.; Utt, M.; Wadström, T. (1998). Sialylglycoconjugate- and proteoglycan-binding microbial lectins. Lectins, Biology, Biochemistry, Clinical Biochemistry, 12: 17th International Lectin Meeting in Würzburg. Hellerup, Denmark: Textop,.
1.1.
1997
Hirmo, S.; Kelm, S.; Wadstrom, T.; Schauer, R. (1997). Lack of evidence for sialidase activity in Helicobacter pylori. FEMS Immunology and Medical Microbiology, 17 (2), 67−72.
1.1.
1997
Wadstrom, T.; Hirmo, S.; Novak, H.; Guzman, A.; RingnerPantzar, M.; Utt, M.; Aleljung, P. (1997). Sulfatides inhibit binding of Helicobacter pylori to the gastric cancer Kato III cell line. Current Microbiology, 34 (5), 267−272.
1.1.
1997
Wadstrom, T.; Hirmo, S.; Nilsson, B. (1997). Biochemical aspects of H-pylori adhesion. Journal of Physiology and Pharmacology, 48 (3), 325−331.
3.2.
1997
Hirmo, S.; Shumakov, Y.; Utt, M.; Wadström, T. (1997). Genetic heterogeneity of Helicobacter pylori and strain typing. In: Moran, A.P.; O´Morain, C.A. (Ed.). Pathogenesis and host response in Helicobacter pylori infections (199−205).. Bad Homburg; Englewood, N.J.: Normed Verlag.
5.1.
1997
Wadstrom, T.; Hirmo, S.; Kelm, S.; Nilsson, B.; Schauer, R.; Utt, M. (1997). Sialylglycoconjugate and heparin binding surface proteins of Helicobacter pylori. European Journal of Cell Biology, 74, 106−106.
1.1.
1996
Wadstrom, T.; Hirmo, S.; Boren, T. (1996). Biochemical aspects of Helicobacter pylori colonization of the human gastric mucosa. Alimentary Pharmacology & Therapeutics, 10, 17−27.
1.1.
1996
Pascu, C.; Hirmo, S.; Ljungh, A.; Wadstrom, T. (1996). A particle agglutination assay for rapid identification of heparin binding to coagulase-negative staphylococci. Journal of Medical Microbiology, 45 (4), 263−269.
1.1.
1996
Hirmo, S.; Kelm, S.; Schauer, R.; Nilsson, B.; Wadstrom, T. (1996). Adhesion of Helicobacter pylori strains to alpha-2,3-linked sialic acids. Glycoconjugate Journal, 13 (6), 1005−1011.
3.2.
1996
Wadström, T.; Hirmo, S. (1996). IV. Bacterial pathogenesis. In: Malfertheiner, P.; Michetti, P.; Price, A. (_EditorsAbbr). Helicobacter pylori: An Atlas (4.1−4.7).. UK: Science Press.
1.1.
1995
Pascu, C.; Hirmo, S.; Ljungh, A.; Wadstrom, T. (1995). Inhibition of extracellular matrix and serum protein binding to staphylococcus aureus by heparin and various polysulphated agents. Medical Microbiology Letters, 4 (8), 397−405.
1.1.
1995
Hirmo, S.; Utt, M.; Ringner, M.; Wadstrom, T. (1995). Inhibition of heparan-sulfate and other glycosaminoglycans binding to helicobacter-pylori by various polysulfated carbohydrates. FEMS Immunology and Medical Microbiology, 10, 301−306.
3.01.2020

Siiri Altraja

https://www.etis.ee/CV/Siiri_Altraja/eng
15.06.1965
737 4313
siiri.altraja@ut.ee

Career

Institutions and positions
1988-91: Junior research fellow, Lab. of
University of Tartu
1991-93: Post-graduate student for degree of
1993-96: Guest researcher, Dept. of Medical
Microbiology, University of Lund, Sweden;
1996-2000: PhD studies, Dept. of Infectious
Gothenburg, Sweden (autumn 1999);
Aberdeen, UK (September 2001)
Immunology, University of Tartu, Estonia;
M.Sc., University of Tartu, Estonia;
Diseases and Medical Microbiology,
University of Lund, Sweden;
From 2001: senior research associate,
Estonian Biocentre
From 2002: senior research associate,
Institute of Molecular and Cell Biology,
Additional research experience: 1) Inst. of
Biochemistry, University of Kiel, Germany,
since March 1994 a total of 8 months;
2). Dept. of NBC Defence at the National
Defence Research Establishment, Umeå,
Sweden and Dept. of Odontology,
University of Umeå, Sweden since Nov.
1996, a total of 5 months; 3). Inst. of
Medical Biochemistry, University of
Aberdeen Proteome Facility, Univerisyt of
01.02.2017–28.03.2018   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Lecturer in General Biochemistry (0,75)
01.01.2016–31.12.2016   
University of Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, Specialist (0,90)
01.04.2015–31.12.2015   
University of Tartu, Faculty of Medicine, Institute of Biomedicine, Specialist (0,90)
01.01.2015–31.03.2015   
University of Tartu, Faculty of Medicine, Institute of Biomedicine, Specialist (1,00)
2013–2013   
University of Tartu, Faculty of Medicine, Departement of General and Molecular Pathology, Chair of Human Biology and Genetics, biotehnoloogia vanemteadur (1,00)
2012–2012   
University of Tartu, Faculty of Medicine, Departement of General and Molecular Pathology, Chair of Human Biology and Genetics, biotehnoloogia vanemteadur
01.03.2007–28.02.2012   
University of Tartu, Faculty of Medicine, Departement of General and Molecular Pathology, Senior Research Fellow in Biotechnology (1,00)
01.11.2006–28.02.2007   
University of Tartu, Faculty of Medicine, Departement of General and Molecular Pathology, Senior Research Fellow extraordinarius (1,00)
01.11.2001–31.10.2006   
University of Tartu, Faculty of Biology and Geography, Institute of Molecular and Cell Biology, Senior Research Fellow (1,00)
 
 
Education
1996–2000   
Full-time PhD student, Dept. of Infectious Diseases and Medical Microbiology, University of Lund, Sweden
1991–1993   
Post-graduate student for a degree of M.Sc, University of Tartu, Estonia
1983–1988   
Graduate student, Dept. of Chemistry, University of Tartu, Estonia; Narrower speciality – biochemistry
 
 
R&D related managerial and administrative work
2003−...   
Expert in the evaluation of the EU grant proposals
2003−...   
Member of the European Respiratory Society
1999−...   
Member of the organisation and teaching staff in PhD course "Microbial Adhesion and Virulence"
2002−2006   
Scientific secretary of the Institute of Molecular and Cell Biology, University of Tartu

Qualifications

Academic degrees
Siiri Altraja, Doctor's Degree, 2000, (sup) Torkel Wadström, Helicobacter pylori sialic acid-specific surface lectin, University of Lund, Sweden.
 
 
Honours & awards
2000, Siiri Altraja, Awarded position in the competition for a "Young Scientist Award" from the President's Culture Fund of Estonia
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.1. Biomedicine
 
 
Additional information
Ph.D (Medicine)
University of Lund, Sweden; 2000

Completed projects

Dissertations under supervision

Supervised dissertations

Publications

Category
Year
Publication
 
1.1.
2018
Kilk, Kalle; Aug, Argo; Ottas, Aigar; Soomets, Ursel; Altraja, Siiri; Altraja, Alan (2018). Phenotyping of Chronic Obstructive Pulmonary Disease Based on the Integration of Metabolomes and Clinical Characteristics. International Journal of Molecular Sciences, 19 (3), ARTN 666.10.3390/ijms19030666.
5.1.
2017
Altraja, S.; Mitt, M.; Altraja, A. (2017). Altered Expression of Genes Involved in Inflammatory Response and Fibrosis by Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Relation to the Effect of Cigarette Smoke. American Journal of Respiratory and Critical Care Medicine, 195, A3070−A3070.
5.1.
2016
Altraja, S.; Mitt, M.; Altraja, A. (2016). Altered gene expression profiles in human bronchial epithelial cells exposed to e-cigarette liquid: results from a genome-wide monitoring. American Journal of Respiratory and Critical Care Medicine, 193, A4053.
5.1.
2016
Altraja, S.; Mitt, M.; Altraja A. (2016). Leukotriene E4 affects expression of genes involved in inflammatory, remodelling and mitogenic responses in human bronchial epithelial cells. European Respiratory Journal, 48 (Suppl.60), PA948.
5.1.
2015
Altraja, S.; Altraja, A. (2015). Bay u9773 and ticagrelor inhibit the LTE4-induced overexpression of the P2Y12 receptor on human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 191, A1277.
5.2.
2015
Altraja, A.; Aug, A.; Kilk, K.; Mahlapuu, R.; Altraja, S.; Soomets, U. (2015). Phenotyping of COPD by integrated metabolomic profiling of exhaled breath condensate and peripheral blood. European Respiratory Journal, 46 (Suppl.59), OA2922.
5.2.
2015
Altraja, S.; Mitt, M.; Altraja, A. (2015). Gene expression changes in human bronchial epithelial cells in response to leukotriene E4. European Respiratory Journal, 46 (Suppl. 59), PA860.
5.2.
2015
Altraja, S.; Mitt, M.; Altraja, A. (2015). General gene expression analysis of human bronchial epithelial cells exposed to different concentrations of leukotriene E4. European Clinical Respiratory Journal, 2, 28179.
5.1.
2014
Aug, A.; Altraja, S.; Kilk, K.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2014). E-cigarettes profoundly affect metabolome of primary human bronchial epithelial cells. European Respiratory Journal, 44 (Suppl. 58), 1834.
1.1.
2013
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2013). Cigarette smoke-induced differential regulation of glutathione metabolism in bronchial epithelial cells is balanced by an antioxidant tetrapeptide UPF1. Experimental and Toxicologic Pathology, 65 (6), 711−717.10.1016/j.etp.2012.09.005.
5.1.
2013
Aug, A.; Altraja, S.; Kilk, K.; Laaniste, L.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2013). Acute effect of cigarette smoke on human bronchial epithelial cell metabolome is reversible by UPF1. European Respiratory Journal, 42, 819s.
5.1.
2013
Altraja, S.; Altraja, A. (2013). Down-regulation of the P2Y12 purinergic receptor expression on human bronchial epithelial cells by transforming growth factor-β. European Respiratory Journal, 42, 1009s−1010s.
5.1.
2013
Altraja, S.; Altraja, A. (2013). Up-regulation of the expression of the P2Y12 purinergic receptor on human bronchial epithelial cells by leukotriene E4. American Journal of Respiratory and Critical Care Medicine, 187, A4191.
5.2.
2013
Altraja, S.; Altraja, A. (2013). Analysis of P2Y12 purinergic receptor expression on human bronchial epithelial cells. Proceedings of the 46th Nordic Lung Congress; (Reykjavik, 13-15 June 2013). 59−60.
1.2.
2012
Altraja, A.; Nigol, K.; Altraja, S.; Viitak, A. (2012). Increased bronchoalveolar lavage fluid tin content in stannosis. Chest Disease Reports, 2 (1), 26−28.10.4081/cdr.2012.e8.
5.2.
2012
Aug, A.; Altraja, S.; Kilk, K.; Laaniste, L.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2012). Antioxidant tetrapeptide UPF1 exerts an immediate effect on cigarette smoke-altered metabolic state of human bronchial epithelial cells. European Respiratory Journal, 40, 837s.
5.2.
2012
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2012). The effect of an antioxidant tetrapeptide UPF1 on glutathione metabolism in human bronchial epithelial cells exposed to cigarette smoke. American Journal of Respiratory and Critical Care Medicine, 185, A1256.
1.1.
2010
Altraja, S.; Jaama, J.; Altraja, A. (2010). Proteome changes of human bronchial epithelial cells in response to pro-inflammatory mediator leukotriene E4 and pro-remodelling factor TGF-β1. Journal of Proteomics, 73 (6), 1230−1240.10.1016/j.jprot.2010.02.017.
5.1.
2010
Altraja, S.; Mahlapuu, R.; Soomets, U.; Altraja, A. (2010). An antioxidant tetrapeptide UPF1 maintains glutathione level in normal human bronchial epithelial cells exposed to oxidative stress. American Journal of Respiratory and Critical Care Medicine, 181, A2686.
1.1.
2009
Altraja, S.; Jaama, J.; Valk, E.; Altraja, A. (2009). Changes in the proteome of human bronchial epithelial cells following stimulation with leukotriene E4 and transforming growth factor-b1. Respirology, 14 (1), 39−45.10.1111/j.1440-1843.2008.01414.x.
3.2.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Changes in the proteome of human bronchial epithelial cells in response to leukotriene E4 and TGF-b1. Marko-Varga, G.; Laurell, T.. Proceedings of 3rd EUPA Congress: Clinical Proteomics (395−397).. Veszprem, Hungary: OOK-PRESS Kft..
5.1.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Cysteinyl leukotrienes cause down-regulation of glucocorticoid receptor in human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 179, A1403.
5.2.
2009
Altraja, S.; Jaama, J.; Altraja, A. (2009). Cysteinyl leukotrienes cause down-regulation of β-tubulin isotype IV in human bronchial epithelial cells. European Respiratory Journal, 34(Suppl.53), 51S.
1.1.
2008
Altraja, S.; Kadai., M; Rekker, E.; Altraja, A. (2008). Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. Respiratory Research, 9 (44), 1−12.10.1186/1465-9921-9-44.
5.2.
2008
Altraja, S.; Jaama, J.; Altraja, A. (2008). Proteome changes of human bronchial epithelial cells in response to leukotriene E4 and TGF-beta1. European Respiratory Journal 32 (Supple 52). 341s.
5.2.
2008
Altraja, S.; Rekker, E.; Altraja, A. (2008). Upregulation of cysteinyl leukotriene receptor expression on human bronchial epithelial cells by cysteinyl leukotrienes alone and with inflammatory cytokines. American Journal of Respiratory and Critical Care Medicine, 177, A16.
5.2.
2007
Altraja, S.; Rekker, E.; Altraja, A. (2007). Cysteinyl leukotriene-induced upregulation of tenascin and laminin beta2 chain in human bronchial epithelial cells is mediated by the CysLT1 receptor. European Respiratory Journal, 30. 217s.
5.2.
2007
Altraja, S.; Valk, E:; Rekker, E.; Altraja, A. (2007). Oxidative stress enhances expression of extracellular matrix proteins in bronchial epithelial cells. European Respiratory Journal, 30. 219s.
5.2.
2007
Altraja, S.; Rekker, E.; Altraja, A. (2007). Cysteinyl leukotriene-induced upregulation of tenascin in human bronchial epithelial cells is mediated by the CysLT1 receptor. American Journal of Respiratory and Critical Care Medicine, 175. A688.
1.1.
2006
Aspholm, M.; Olfat, F.O.; Nordén, J.; Sondén, B.; Lundberg, C.; Sjöström, R.; Altraja, S.; Odenbreit, S.; Haas, R.; Wadström, T.; Engstrand, L.; Semino-Mora, C.; Liu, H.; Dubois, A.; Teneberg, S.; Arnqvist, A.; Borén, T. (2006). SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathogens, 2 (10), 0989−1001.
5.2.
2006
Altraja, S; Rekker, E; Altraja, A. (2006). Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-b1 and LTE4 on human bronchial epithelial cells. European Respiratory Journal, 28. 564s. ((Suppl. 50)).
5.2.
2006
Altraja, S.; Valk, E.; Altraja, A. (2006). Changes in the proteome of human bronchial epithelial cells in response to proinflammatory mediators. Proceedings of the American Thoracic Society, 3. A309.
5.2.
2005
Altraja, S.; Kadai, M.; Altraja, A. (2005). Expression of the cysteinyl leukotriene receptors CysLT1 and CysLT2 in the airway structural cells. European Respiratory Journal, 26, 346s.
5.2.
2005
Altraja, S.; Rekker, E.; Altraja, A. (2005). Cysteinyl leukotrienes enhance expression of tenascin and laminin beta2 chain by human lung fibroblasts. Proceedings of the American Thoracic Society. A76. (2).
5.2.
2004
Altraja, A.; Kadai, M.; Altraja, S. (2004). Cysteinyl leukotrienes increase tenascin expression by human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine, 169. A454. (Supplement).
5.2.
2004
Altraja, S.; Kadai, M.; Altraja, A. (2004). Oxidative stress in bronchial epithelial cells: relations to extracellular matrix synthesis. European Respiratory Journal, 48. 106s. (24).
5.2.
2003
Altraja, S.; Kadai, M.; Altraja, A. (2003). Leukotriene E4 increases tenascin production by human bronchial epithelial cells. European Respiratory Journal. 36s. (22).
1.1.
2002
Mahdavi, J.; Forsberg, L.; Teneberg, S.; Karlsson, KA.; Altraja, S.; et, al. (2002). Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science, 297 (5581), 573−578.
1.1.
2001
Wang, X.; Hirmo, S.; Willen, R.; Wadstrom, T. (2001). Inhibition of Helicobacter pylori infection by bovine milk glycoconjugates in a BALB/cA mouse model. Journal of Medical Microbiology, 50 (5), 430−435.
1.1.
2001
Annuk, H.; Hynes, SO.; Hirmo, S.; Mikelsaar, M.; Wadstrom, T. (2001). Characterisation and differentiation of lactobacilli by lectin typing. Journal of Medical Microbiology, 50 (12), 1069−1074.
3.2.
2001
Arnqvist, A.; Ilver, D.; Ögren, J.; Hirmo, S.; Wadström, T.; Boren, T. (2001). Adherence of Helicobacter pylori: Mechanisms and Relevance to Pathogenesis. In: Moran, A.P. (_EditorsAbbr). Helicobacter 2001:Past, Present and Future (CD-ROM).. Englewood, NJ, USA: Normed Verlag Inc, Englewood.
3.2.
2001
Gerhard, M.; Hirmo, S.; Wadström, T.; Miller-Podraza, H.; Teneberg, S.; Karelsson, K.; Appelmelk, B.; Odenbreit, S.; Haas, R.; Arnqvist, A.; Boren, T. (2001). Helicobacter pylori, An Adherent Pain in the Stomach. In: Helicobacter pylori: Molecular and Cellular Biology (185−206).. Norfolk, U.K. : Horizon Scientific Press.
5.1.
2000
Wang, X.; Hirmo, S.; Willen, R.; Wadstrom, T. (2000). Inhibition of H-pylori infection by bovine milk glycoconjugates in a mouse model. GUT, 47, A60−A60.
1.1.
1999
Annuk, H.; Hirmo, S.; Turi, E.; Mikelsaar, M.; Arak, E.; Wadstrom, T. (1999). Effect on cell surface hydrophobicity and susceptibility of Helicobacter pylori to medicinal plant extracts. FEMS Microbiology Letters, 172 (1), 41−45.
1.1.
1999
Hirmo, S.; Artursson, E.; Puu, G.; Wadstrom, T.; Nilsson, B. (1999). Helicobacter pylori interactions with human gastric mucin studied with a resonant mirror biosensor. Journal of Microbiological Methods, 37 (2), 177−182.
1.1.
1999
Hynes, SO.; Hirmo, S.; Wadstrom, T.; Moran, AP. (1999). Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. Journal of Clinical Microbiology, 37 (6), 1994−1998.
1.1.
1998
Hirmo, S.; Artursson, E.; Puu, G.; Wadstrom, T.; Nilsson, B. (1998). Characterization of Helicobacter pylori interactions with sialylglycoconjugates using a resonant mirror biosensor. Analytical Biochemistry, 257 (1), 63−66.
1.1.
1998
Hirmo, S.; Kelm, S.; Iwersen, M.; Hotta, K.; Goso, Y.; Ishihara, K.; Suguri, T.; Morita, M.; Wadstrom, T.; Schauer, R. (1998). Inhibition of Helicobacter pylori sialic acid-specific haemagglutination by human gastrointestinal mucins and milk glycoproteins. FEMS Immunology and Medical Microbiology, 20 (4), 275−281.
3.1.
1998
Chmiela, M.; Paziak-Domanska, B.; Hirmo, S.; Rudnicka, W.; Utt, M.; Wadström, T. (1998). Helicobacter pylori - interactions with phagocytes. In: Hunt R.H., Tytgat G.N.J. (Ed.). Helicobacter pylori : basic mechanisms to clinical cure 1998 (90−100).. Dordrecht, Boston, London: Kluwer Academic Publishers.
3.4.
1998
Hirmo, S.; Utt, M.; Wadström, T. (1998). Sialylglycoconjugate- and proteoglycan-binding microbial lectins. Lectins, Biology, Biochemistry, Clinical Biochemistry, 12: 17th International Lectin Meeting in Würzburg. Hellerup, Denmark: Textop,.
1.1.
1997
Hirmo, S.; Kelm, S.; Wadstrom, T.; Schauer, R. (1997). Lack of evidence for sialidase activity in Helicobacter pylori. FEMS Immunology and Medical Microbiology, 17 (2), 67−72.
1.1.
1997
Wadstrom, T.; Hirmo, S.; Novak, H.; Guzman, A.; RingnerPantzar, M.; Utt, M.; Aleljung, P. (1997). Sulfatides inhibit binding of Helicobacter pylori to the gastric cancer Kato III cell line. Current Microbiology, 34 (5), 267−272.
1.1.
1997
Wadstrom, T.; Hirmo, S.; Nilsson, B. (1997). Biochemical aspects of H-pylori adhesion. Journal of Physiology and Pharmacology, 48 (3), 325−331.
3.2.
1997
Hirmo, S.; Shumakov, Y.; Utt, M.; Wadström, T. (1997). Genetic heterogeneity of Helicobacter pylori and strain typing. In: Moran, A.P.; O´Morain, C.A. (Ed.). Pathogenesis and host response in Helicobacter pylori infections (199−205).. Bad Homburg; Englewood, N.J.: Normed Verlag.
5.1.
1997
Wadstrom, T.; Hirmo, S.; Kelm, S.; Nilsson, B.; Schauer, R.; Utt, M. (1997). Sialylglycoconjugate and heparin binding surface proteins of Helicobacter pylori. European Journal of Cell Biology, 74, 106−106.
1.1.
1996
Wadstrom, T.; Hirmo, S.; Boren, T. (1996). Biochemical aspects of Helicobacter pylori colonization of the human gastric mucosa. Alimentary Pharmacology & Therapeutics, 10, 17−27.
1.1.
1996
Pascu, C.; Hirmo, S.; Ljungh, A.; Wadstrom, T. (1996). A particle agglutination assay for rapid identification of heparin binding to coagulase-negative staphylococci. Journal of Medical Microbiology, 45 (4), 263−269.
1.1.
1996
Hirmo, S.; Kelm, S.; Schauer, R.; Nilsson, B.; Wadstrom, T. (1996). Adhesion of Helicobacter pylori strains to alpha-2,3-linked sialic acids. Glycoconjugate Journal, 13 (6), 1005−1011.
3.2.
1996
Wadström, T.; Hirmo, S. (1996). IV. Bacterial pathogenesis. In: Malfertheiner, P.; Michetti, P.; Price, A. (_EditorsAbbr). Helicobacter pylori: An Atlas (4.1−4.7).. UK: Science Press.
1.1.
1995
Pascu, C.; Hirmo, S.; Ljungh, A.; Wadstrom, T. (1995). Inhibition of extracellular matrix and serum protein binding to staphylococcus aureus by heparin and various polysulphated agents. Medical Microbiology Letters, 4 (8), 397−405.
1.1.
1995
Hirmo, S.; Utt, M.; Ringner, M.; Wadstrom, T. (1995). Inhibition of heparan-sulfate and other glycosaminoglycans binding to helicobacter-pylori by various polysulfated carbohydrates. FEMS Immunology and Medical Microbiology, 10, 301−306.
3.01.2020
Detailne otsing
  • Leitud 9 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
SFSF0182560s03Geneetilised ja rakulised haiguste põhjused, rakkude diferentseerumine ja tüvirakud teraapias01.01.200331.12.2007Aavo-Valdur MikelsaarTartu Ülikool, Arstiteaduskond477 675,66 EUR
SFSF0180096s08Inimese fetaalsete neuraalsete ja embrüonaalsete tüvirakkude differentseerumine neuraalses suunas ja uute immuunmarkerite loomine01.01.200831.12.2013Erkki JuronenTartu Ülikool, Arstiteaduskond483 282,82 EUR
SFSF_0182582As03Inimese Genoom II01.01.200331.12.2007Andres MetspaluTartu Ülikool, Bioloogia-geograafiateaduskond0,00 EUR
SFSF0182582As03Inimese Genoom II01.01.200331.12.2007Andres MetspaluTartu Ülikool, Bioloogia-geograafiateaduskond328 505,88 EUR
ETFETF9043Kroonilise obstruktiivse kopsuhaiguse fenotüpiseerimine metaboloomi profiili alusel01.01.201231.12.2015Alan AltrajaTartu Ülikool, Arstiteaduskond72 960,00 EUR
MUULARMP12232Projekti BOSS (BOVINE SPERM SEXING) raames polü- ja monoklonaalsete antikehade loomine pulli X- ja/või Y-kromosoomi kandvate spermide vastu01.10.201231.12.2014Aavo-Valdur MikelsaarTartu Ülikool; Tartu Ülikool, Arstiteaduskond93 360,00 EUR
ETFETF7154Struktuursete rakkude talitlus hingamisteede remodelleerumisel astma ja kroonilise obstruktiivse kopsuhaiguse (KOK) korral: proteoomi analüüs01.01.200731.12.2010Siiri AltrajaTartu Ülikool, Arstiteaduskond60 128,08 EUR
ETFETF9103Tsüsteinüülleukotrieenide hingamisteede remodelleerumist soodustava toime retseptorvahendatus inimese hingamisteede epiteelrakkudes 01.01.201231.12.2015Siiri AltrajaTartu Ülikool, Arstiteaduskond86 400,00 EUR
ETFETF6566Tsüsteinüülleukotrieenide ja nende retseptorite osalus inimese hingamisteede põletikulises remodelleerumises – võimalikud mehhanismid ja farmakoloogilise mõjutamise sihtmärgid01.01.200631.12.2009Alan AltrajaTartu Ülikool, Arstiteaduskond69 605,60 EUR